Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program.
The clinical-stage biopharmaceutical company said numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL Fatigue scores.
"Intranasal foralumab is continuing to show clinical improvements over time in patients with na-SPMS where foralumab targets inflammation in the brain," Tiziana Life Sciences acting CEO Gabriele Cerrone said in a statement.
"Based on the totality of the clinical results seen to-date, I am hopeful that intranasal foralumab and its anti-inflammatory mechanism of action could provide relief to na-SPMS patients that currently have no available therapies," Cerrone added.
Tiziana noted the results follow previously announced positive six-month PET scan data, which was presented at ECTRIMS (39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis) on October 11, 2023.
Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T-cell receptor and dampens inflammation by modulating T-cell function, thereby suppressing effector features in multiple immune cell subsets, according to the company.
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.
Contact Sean at sean@proactiveinvestors.com